Approximately 701 patients will participate in this study worldwide and it is estimated to be completed in June 2018. This study is currently recruiting participants. Read more.
![[Unlock]](/wp-content/uploads/2017/08/human_box.png "Unlock")
I AM A HUMAN AND NOT A ROBOT![[Locked]](/wp-content/uploads/2017/02/lock.png "Locked")
⇧ Checking the box is REQUIRED for validation.
What is MLN9708?
MLN9708 is an investigational targeted anti-cancer drug given orally. MLN9708 is being studied in multiple myeloma, various hematologic malignancies, and solid tumors.
What is multiple myeloma?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. Plasma cells normally make proteins called antibodies to help you fight infections. Read more.
What is the official title of this study?
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Jul 9, 2013 – This study is currently recruiting participants. Verified July 2013 by Millennium Pharmaceuticals, Inc. Sponsor: Millennium Pharmaceuticals, Inc. Identifier: NCT01850524